Drug Trial Radar · NCT05702073
To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.
Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
423
Actual
Start
Mar 31, 2023
Primary completion
Jun 11, 2024
Study completion Jun 11, 2024
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with basal insulin compared to insulin Glargine QD for 26weeks.
Conditions
- Type 2 Diabetes Mellitus
Interventions
INS068 injectionDrug
INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial
Insulin GlargineDrug
Insulin Glargine injected subcutaneously once daily. Treat-to-target dose titration during the trial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: Week 0 to Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.